Raymond James Financial
PTCT icon

Raymond James Financial’s PTC Therapeutics PTCT Stock Holding History

Raymond James Financial’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.68M Buy
69,660
+17,205
+33% +$1.24M ﹤0.01% 2630
2026
Q1 		$3.57M Sell
52,455
-33,543
-39% -$2.38M ﹤0.01% 2880
2025
Q4 		$6.53M Buy
85,998
+2,873
+3% +$209K ﹤0.01% 2295
2025
Q3 		$5.1M Sell
83,125
-2,596
-3% -$135K ﹤0.01% 2437
2025
Q2 		$4.19M Buy
85,721
+29,694
+53% +$1.41M ﹤0.01% 2493
2025
Q1 		$2.86M Buy
56,027
+7,299
+15% +$364K ﹤0.01% 2730
2024
Q4 		$2.2M Buy
+48,728
New +$2.09M ﹤0.01% 2897

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Raymond James Financial's PTCT Position: Q2 2026 in Review

Raymond James Financial increased its PTC Therapeutics (PTCT) stake by 33% in Q2 2026, buying an estimated $1.24M and bringing the position to 69,660 shares worth $5.68M. The position accounts for ﹤0.01% of the portfolio, ranked #2630.

Raymond James Financial first reported a position in PTCT in Q4 2024 and has held it in 7 quarters since. The position peaked at $6.53M in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Raymond James Financial held 69,660 shares of PTC Therapeutics worth $5.68M as of Q2 2026.
  • Raymond James Financial bought 17,205 PTC Therapeutics shares in Q2 2026, an estimated $1.24M.
  • PTC Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #2630 holding.
  • Raymond James Financial first reported a position in PTC Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's PTC Therapeutics position peaked at $6.53M in Q4 2025.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.